BFM
CRVS icon

Boothbay Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Boothbay Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-98,000
Closed -$312K – 1511
2025
Q1 		$312K Sell
98,000
-120,600
-55% -$568K 0.01% 1051
2024
Q4 		$1.17M Buy
218,600
+154,800
+243% +$1.16M 0.03% 596
2024
Q3 		$337K Buy
+63,800
New +$229K 0.01% 1162

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's CRVS Position: Q2 2022 in Review

Boothbay Fund Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2022, closing a stake of 48,211 shares — an estimated $79K sold.

Boothbay Fund Management first reported a position in CRVS in Q1 2021 and held it in 5 quarters. The position peaked at $366K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2022.

  • Boothbay Fund Management reported no remaining Corvus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 48,211 Corvus Pharmaceuticals shares in Q2 2022, an estimated $79K.
  • Boothbay Fund Management first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Boothbay Fund Management's Corvus Pharmaceuticals position peaked at $366K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.